key: cord-0914202-a87dmm14
authors: Hartung, Hans-Peter
title: Ocrelizumab shorter infusion: Primary results from the ENSEMBLE PLUS substudy in patients with MS
date: 2020-06-04
journal: Neurol Neuroimmunol Neuroinflamm
DOI: 10.1212/nxi.0000000000000807
sha: 5af4f9f25a2b24b5a7d20dd3120e597b250806e7
doc_id: 914202
cord_uid: a87dmm14

OBJECTIVE: To assess the safety of ocrelizumab (OCR) shorter duration infusion in patients with MS. METHODS: ENSEMBLE PLUS is a randomized, double-blind substudy to the single-arm ENSEMBLE study (NCT03085810). In ENSEMBLE, patients with early stage relapsing-remitting MS received OCR 600 mg initially as two 300 mg IV infusions 2 weeks apart and subsequently as a single 3.5-hour 600 mg infusion every 24 weeks for 192 weeks. In ENSEMBLE PLUS, OCR 600 mg administered over the approved 3.5-hour infusion time (conventional duration) is compared with a 2-hour infusion (shorter duration). The primary end point was the proportion of patients with infusion-related reactions (IRRs) after the first randomized dose (assessed during and up to 24 hours postinfusion). RESULTS: From November 1, 2018, to September 27, 2019, 580 patients were randomized 1:1 to the conventional or shorter infusion group. After the first randomized dose, 67 of 291 patients (23.1%) in the conventional and 71 of 289 patients (24.6%) in the shorter infusion group experienced IRRs. Most IRRs were mild or moderate in both groups; one patient in each group experienced a severe IRR, and in both groups, 98.6% (136 of 138) of all IRRs resolved without sequelae. No IRRs were serious, life-threatening, or fatal. No IRR-related discontinuation occurred. During the first randomized dose, 14 of 291 (4.8%) and 25 of 289 (8.7%) patients in the conventional and shorter infusion groups, respectively, had IRRs leading to infusion slowing/interruption. CONCLUSION: The frequency and severity of IRRs were similar between conventional and shorter OCR infusions. Shortening the infusion time to 2 hours reduces the total infusion site stay time and lessens the overall patient and site staff burden. CLASSIFICATION OF EVIDENCE: This interventional study provides Class I evidence that the frequency and severity of IRRs were similar at the first randomized dose using OCR (600 mg) infusions of conventional and shorter duration in patients with relapsing-remitting MS. CLINICAL TRIAL IDENTIFIER NUMBER: NCT03085810.

Ocrelizumab (OCR) is a humanized anti-CD20 monoclonal antibody approved uniquely for both relapsing and primary progressive MS. 1, 2 The current OCR infusion schedule, including mandatory premedication 1-hour preinfusion and 1-hour postinfusion observations, requires an on-site stay of 5.5-6 hours. Shortened infusion times can minimize the treatment burden for patients, reduce the time required at the infusion site, and lead to decreased workloads for site staff, without compromising patient safety. [3] [4] [5] Here, we describe the primary findings from the ENSEMBLE PLUS study evaluating the safety, including infusion-related reactions (IRRs), of a shorter vs conventional infusion of OCR in patients with early relapsing-remitting MS (RRMS).

The ENSEMBLE PLUS substudy is a prospective, multicenter, randomized, double-blind phase IIIb study designed to evaluate the safety of a shorter duration infusion of OCR in patients with early stage RRMS enrolled in the main ENSEMBLE study. In ENSEMBLE, treatment-naïve patients (age 18-55 years) with a confirmed diagnosis of RRMS, 6 disease duration ≤3 years, one or more relapses/signs of MRI activity in the previous 12 months, and an Expanded Disability Status Scale score of 0-3.5 (inclusive) received OCR 600 mg infusions every 24 weeks for 192 weeks (up to 8 doses), with mandatory premedication. Patients with a previous serious OCR-related IRR were excluded from the substudy. The target enrollment was 700 patients in the ENSEMBLE PLUS substudy, which included 150 patients already enrolled in the main ENSEMBLE study plus 550 newly enrolled patients.

In all patients, the first dose of OCR was administered, per label, as an initial dose of two 300 mg infusions, separated by 14 days (figure 1A). Randomization was performed with the use of an interactive web response system in permuted blocks (block size = 4). Randomization to either the conventional or shorter infusion group occurred at week 24 for newly enrolled patients. For patients already enrolled in the main ENSEM-BLE study, randomization occurred at their next scheduled infusion (week 48, 72, 96, or 120). Patients eligible to take part in this substudy were randomized (1:1) into conventional 3.5-hour and shorter 2-hour infusion groups stratified by region (United States, Canada, and Australia vs the rest of the world) and dose at which the patient is randomized. Patients received 600 mg OCR in 500 mL 0.9% sodium chloride infused over approximately 3.5 hours in the conventional infusion group (with a mimic switch infusion at approximately 2 hours) or 2 hours, followed by a 100 mL 0.9% sodium chloride infusion over the remaining 1.5 hours in the shorter infusion group, every 24 weeks for the remainder of the study duration (figure 1B). Blood samples were only collected at the first OCR infusion postrandomization and 30 minutes after the completion of the shorter and conventional infusion, representing the peak concentration (Cmax) of OCR.

Patients, site personnel, and sponsor employees remained blinded during the study. Infusions were preloaded and placed into standardized infusion cover bags on an infusion rack; the infusion administration pump was covered and operated only by an unblinded infusion nurse.

Standard protocol approvals, registrations, and patient consents The relevant institutional review boards/ethics committees approved the trial protocols (NCT03085810). All patients provided written informed consent. The Steering Committee and study investigators gathered the data, and the sponsor performed the data analyses. The author and Steering Committee agreed to submit the manuscript for publication.

The primary research question provides Class I evidence to determine if the frequency and severity of IRRs after the first randomized dose differed using OCR (600 mg) infusions of conventional and shorter duration in patients with RRMS. The primary end point was the proportion of patients with IRRs during or within 24 hours after the first randomized dose using shorter vs conventional duration OCR infusion groups (IRRs assessed during and 24 hours postinfusion). Secondary end points include the severity and symptoms of IRRs, IRRs leading to treatment discontinuation, the proportion of patients with IRRs overall, and the overall safety.

IRRs were classified as occurring during infusion or within 24 hours after the end of the infusion (collected by follow-up telephone contact). IRR events occurring in a patient at both time points (during and postinfusion) were reported as 2 separate IRRs per infusion. Safety was assessed through the monitoring and recording of adverse events (AEs) and serious AEs. AEs were defined as all AEs including IRRs and serious MS relapses, but excluding nonserious MS relapses. AEs were reported from the first randomized dose onward up to the interim clinical cutoff date (iCCOD).

The proportion of patients with IRRs that occurred during or within 24 hours after the first randomized dose of OCR were Glossary AE = adverse event; iCCOD = interim clinical cutoff; IRR = infusion-related reaction; ITT = intent-to-treat; OCR = ocrelizumab; RRMS = relapsing-remitting MS.

summarized as point estimates of the between-treatment difference and associated symmetric 2-sided 95% CIs. All summaries of IRRs are based on the intent-to-treat (ITT) population; overall AEs are based on the safety population. Analyses are based on patients who had completed the 24-hour evaluation period after the first randomized dose by the prespecified iCCOD of September 27, 2019. A descriptive analysis (mean and median in patients with/without IRR) was used to describe any association between the Cmax of OCR vs IRR maximum intensity.

The authors confirm that the data supporting the findings of this study are available within the article and from the corresponding author on reasonable request.

Qualified researchers may request access to individual patientlevel data through the clinical study data request platform (https://vivli.org/). Further details on the Roche criteria for eligible studies are available here (https://vivli.org/members/ ourmembers/). For further details on Roche Global Policy on the Sharing of Clinical Study Information and how to request access to related clinical study documents, see roche.com/ research_and_development/who_we_are_how_we_work/ clinical_trials/our_commitment_to_data_sharing.htm. One patient disclosed that they were pregnant after randomization but before receiving any study treatment. Per protocol, treatment is withheld from patients who become pregnant during the study. There was also one withdrawal from the conventional infusion group because of an adverse event (depressive symptom) that was considered unrelated to the study treatment but because of concurrent illness of depression. A discontinuation visit had not been scheduled or undertaken for the patient at the time of CCOD; hence, this patient could not be included in any of the tables which display discontinuation. Other: accidental unblinding. CCOD = clinical cutoff date. IRRs leading to withdrawal from OCR treatment at the first randomized dose 0 0

IRRs leading to withdrawal from OCR treatment at any randomized dose 0 0

Abbreviations: AE = adverse event; IRR = infusion-related reaction; ITT = intent-to-treat; OCR = ocrelizumab. All patients, ITT population. a The stratified estimated difference between the proportions in the 2 randomized groups is the weighted average of the proportion difference across strata (region and dose at which the patient is randomized) based on Cochran-Mantel-Haenszel weights. b Most frequent symptoms, i.e., in ≥10% of patients with IRRs. c Percentages of patients with any symptoms are based on the number of patients with any IRR. d Percentages of patients with any symptomatic treatments are based on the number of patients with any symptomatic treatment for any IRR. e Summaries of safety data were performed using the safety population, which included all randomized patients who received any dose or a part of a dose of ocrelizumab (N = 291 shorter infusion group and N = 288 conventional infusion group). One patient in the conventional infusion group who did not receive treatment was excluded from the safety population. Two patients in the shorter infusion group received the wrong treatment they were randomized to, so the N for ITT differs from the N for safety population. The most frequent symptoms associated with IRRs in both groups were throat irritation, fatigue, and headache, with the most common treatments being paracetamol, diphenhydramine hydrochloride, and chlorpheniramine (table) . Overall, n = 14 of 291 (4.8%) and n = 25 of 289 (8.7%) patients in the conventional and shorter infusion groups had IRRs leading to temporary infusion interruption/slowing, respectively (table) . There was no correlation between peak serum OCR concentration and observed IRRs.

Overall, the AE profile between conventional and shorter infusion groups was balanced; the most common AEs in either infusion group were IRRs (table). One patient (0.3%) from the conventional infusion group withdrew because of an AE (depressive symptom). Serious AEs occurred in n = 3 (1.0%) patients in both groups (conventional infusion: events, n = 1 typhoid fever and intraductal papilloma of breast, n = 2 depressive symptoms; shorter infusion: events, n = 1 urinary tract infection, peripheral edema, and hypotension).

This primary analysis of the ENSEMBLE PLUS study shows that the frequency, severity, and symptoms of IRRs were similar between conventional and shorter OCR infusion periods. During the first randomized dose, there was a moderately higher incidence of IRRs leading to infusion slowing/ interruption in the shorter (25 of 289 patients; 8.7%) vs conventional (14 of 291 patients; 4.8%) infusion group. Overall, AEs were consistent with the known safety profile of OCR, [7] [8] [9] and no new safety signals were observed with a shorter infusion time. The safety profile of OCR remains unchanged. Shortening the OCR infusion time to 2 hours may reduce the total site stay time and lessen the burden on patients and site staff, which is of particular importance in light of the current coronavirus disease 2019 pandemic.

The author thanks all patients, their families, and the investigators who participated in this trial (including the ENSEMBLE PLUS study Steering Committee, which provided study oversight). The author also thanks the independent data monitoring committee for performing data analysis and safety monitoring, and is grateful to Regine Buffels and Jad Abdul Samad (of F. Hoffmann-La Roche Ltd) for additional critical review of this manuscript and technical advice. 

Ocrevus (package insert)

Ocrevus (summary of product characteristics)

Safety of infusing rituximab at a more rapid rate in patients with rheumatoid arthritis: results from the RATE-RA study

Rapid infusion rituximab in combination with corticosteroid-containing chemotherapy or as maintenance therapy is well tolerated and can safely be delivered in the community setting

Rapid infusion of rituximab over 60 min

Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria

Ocrelizumab infusion experience in patients with relapsing and primary progressive multiple sclerosis: results from the phase 3 randomized OPERA I, OPERA II, and ORATORIO studies

Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis

Ocrelizumab versus placebo in primary progressive multiple sclerosis